Shares of Merck slid Tuesday in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...

RAHWAY, N.J. (AP) — RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had ...

New Jersey, company. For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda ...

We recently compiled a list of the 10 Best Dow Jones Dividend Stocks According to Wall Street Analysts. In this article, we ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...

Merck (NYSE:MRK) shares fell nearly 8% Tuesday ... to China from February through at least mid-year. The Rahway, New Jersey-based pharma giant projects worldwide sales in the range of $64.1B ...

Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...

For 2025 Merck, based in , Rahway, New Jersey, expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 billion in sales. Analysts had been projecting ...